Rod Nordland, famed journalist who wrote about his glioblastoma, has died
Rod Nordland wrote about his experience with glioblastoma in his book “Waiting for the Monsoon.”
Rod Nordland wrote about his experience with glioblastoma in his book “Waiting for the Monsoon.”
OurBrainBank is at ASCO2025 presenting a poster on inequities in glioblastoma treatment. Visit our booth and say hello to Executive Director Kelli Duprey.
OurBrainBank, in collaboration with a team from Imperial College London, is conducting innovative research to better understand the experience of adult brain tumour patients from the UK, some of whom may be accessing treatment outside of the standard care that is offered by the NHS.
MAY is Brain Tumor Awareness Month: give, share, raise awareness about glioblastoma
Join us on June 5, 2025 in Brooklyn to celebrate Jessica Morris’s memoir of living with glioblastoma ALL IN MY HEAD. Readings and conversation with a GBM care partner and a top neuro-oncologist from Columbia University.
Read the letter conductor Michael Tilson Thomas posted. He’s has been open about his glioblastoma diagnosis with his many fans around the world.
Connect with others also affected by glioblastoma—give and get support, information, and resources.
Remembering Adam Hayden, a giant in the glioblastoma community (1982-2025)
In 2025 we met with people living with GBM and their care partners, traveled to conferences, and began to tell the world about our GBM Disparities Survey.
“It was incredibly energizing to see how OBB’s work is not only documenting problems but also driving conversations and initiatives that could improve access to care and quality of life for GBM patients across diverse communities.” Jacob Ellen writes about his experience with the SNO 2025 conference where OurBrainBank presented two posters and won an award.
OurBrainBank 2025 press release about disparities in GBM treatment across the USA. Survey of 500+ patients and care partners show inequities — many Americans are not offered their best chance via a clinical trial, second opinion, and other factors.
